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Abstract
Background: Keratins 8 and 18 (K8/K18) are intermediate filament proteins that protect the liver from various forms of
injury. Exonic K8/K18 variants associate with adverse outcome in acute liver failure and with liver fibrosis progression in
patients with chronic hepatitis C infection or primary biliary cirrhosis. Given the association of K8/K18 variants with end-
stage liver disease and progression in several chronic liver disorders, we studied the importance of keratin variants in
patients with hemochromatosis.
Methods: The entire K8/K18 exonic regions were analyzed in 162 hemochromatosis patients carrying homozygous C282Y
HFE (hemochromatosis gene) mutations. 234 liver-healthy subjects were used as controls. Exonic regions were PCR-
amplified and analyzed using denaturing high-performance liquid chromatography and DNA sequencing. Previously-
generated transgenic mice overexpressing K8 G62C were studied for their susceptibility to iron overload. Susceptibility to
iron toxicity of primary hepatocytes that express K8 wild-type and G62C was also assessed.
Results: We identified amino-acid-altering keratin heterozygous variants in 10 of 162 hemochromatosis patients (6.2%) and
non-coding heterozygous variants in 6 additional patients (3.7%). Two novel K8 variants (Q169E/R275W) were found. K8
R341H was the most common amino-acid altering variant (4 patients), and exclusively associated with an intronic KRT8
IVS7+10delC deletion. Intronic, but not amino-acid-altering variants associated with the development of liver fibrosis. In
mice, or ex vivo, the K8 G62C variant did not affect iron-accumulation in response to iron-rich diet or the extent of iron-
induced hepatocellular injury.
Conclusion: In patients with hemochromatosis, intronic but not exonic K8/K18 variants associate with liver fibrosis
development.
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Introduction
Intermediate filaments (IFs), together with microtubules and the
actin-containing microfilaments constitute the three major com-
ponents of eukaryotic cytoskeleton [1]. Keratins (KRT genes, K
proteins) represent the IFs of epithelial cells and are further
subdivided into subtypes II (including K1–K8 and K71–K80) and
I (K9–K28), which are both required to form obligate hetero-
polymers [2,3]. Consequently, each epithelial cell expresses at least
one type I and one type II keratin [2,3]. Adult hepatocytes are
unique, in that they contain K8/K18 as their only cytoplasmic IFs,
while most other cell types display a more complex keratin
composition [3]. The simple hepatocellular keratin expression
pattern accounts for the observation that animals either lacking
K8/K18 or expressing mutant K8/K18 display a predominant
hepatic phenotype [4]. These animal findings spurred human
association studies, which identified K8/K18 variants to be
overrepresented in patients with cryptogenic and non-cryptogenic
liver cirrhosis [4]. Subsequent reports showed that the presence of
K8/K18 variants predisposes to liver fibrosis development in
patients with chronic hepatitis C and primary biliary fibrosis as
well as to adverse outcome of acute liver failure [5,6,7]. Keratin
variants display ethnicity-specific distribution with K8 G62C/
R341H and K8 Y54H/G434S being the most common amino-
acid altering variants in Caucasians and African-American
patients, respectively [7].
The pathogenesis of keratin variants was supported by the
transgenic mice overexpressing K8 G62C variant, which are
susceptible to Fas-induced apoptosis and microcystin-induced liver
injury [8]. Presence of keratin variants predisposes to selective
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injury; and thioacetamide- but not carbon tetrachloride-induced
liver fibrosis development [9,10]. This suggests that the presence of
keratin variants may predispose to specific liver diseases, while
other liver disorders might be resistant to keratin mutation. To test
this hypothesis, we studied the role of keratin variants in patients
with hereditary hemochromatosis (HHC).
Hereditary hemochromatosis (HHC) comprises genetic disor-
ders leading to iron overload [11]. The most frequent cause of
HHC is the homozygous C282Y mutation in the HFE gene, which
is as frequent as 1:200 in Caucasians of northern European
descent [11,12]. Homozygous carriers of this mutation present
with elevated transferrin saturation, ferritin and serum iron levels
[11,12]. Epidemiological studies demonstrated that the clinical
penetrance of HFE mutations is highly variable and does not
necessarily lead to a clinically-manifest iron overload or even
development of end-stage liver disease [11,12]. Additional
modifying factors including gender, alcohol consumption or co-
infection with hepatitis C virus are involved [11,12]. In addition,
polymorphic variants of genes coding for modulators of iron
metabolism, oxidative stress and certain cytokines were also shown
to affect disease development [13,14,15].
In a study that examined candidate gene variants that may
associate with the presence of HHC, the K8 R341H heterozygous
variant was identified in 3 of 13 iron overload subjects but not in 5
controls [16]. This K8 variant was then examined in 119 subjects
with the C282Y/C282Y HFE mutation and 116 age-, sex- and
ethnic background matched controls. In that group, 9 patients in
the HHC cohort carried the K8 R341H variant but none in the
controls [16]. However, the frequency of the K8 R341H in more
than 800 controls was 3.1% [5]. Notably, iron overload in HHC
patients is known to generate reactive oxygen species [17,18], and
earlier findings demonstrate that mice that overexpress the K18
R90C variant manifest upregulation of hepatic oxidative injury
gene products under basal conditions [17,18]. These collective
findings led us to analyze a cohort of 162 HHC patients from
central Europe for the presence of keratin variants, and to evaluate
the impact of iron overload in previously established transgenic
mice overexpressing the human K8 G62C variant.
Methods
Ethics statement
The study protocol was reviewed and approved by the local
ethics committees of the participating centers Austria (Vienna,
Salzburg, and Innsbruck) and Germany (Regensburg, Erlangen)
between 1991–2005, and all recruited patients gave informed and
written consent.
All animal experiments were conducted with the approval of
UCUCA under animal protocol number 10081 (Michigan, USA)
for animal welfare.
Hemochromatosis Patient Cohort and Control Subjects
To determine the impact of keratin variants on liver disease
development in HHC, we analyzed a previously described cohort
of 162 homozygous carriers of the HFE C282Y mutation [19,20].
The analyzed subjects were recruited in five medical centers in
Austria (Vienna, Salzburg, and Innsbruck) and Germany (Regens-
burg, Erlangen) between 1991–2005. The presence of the HFE
mutation of the analyzed subjects was confirmed by standard
genetic testing [21]. All patients underwent liver biopsy and the
liver sections were evaluated by two independent pathologists
[19,20] as described by Ishak et al. [22], with fibrosis stages 5 and
6 being considered as cirrhosis. Serum iron, ferritin, and
transferrin levels were measured by routine commercial testing.
Hepatic iron concentration (HIC) was measured by atomic
absorption spectrometry [23], and is expressed as mg/g of dry
liver tissue weight. The hepatic iron index (HII) was calculated by
dividing the HIC by the age of the patients (in years) and by the
molecular weight of iron. Transferrin saturation was calculated as
follows: (serum iron670.9)/(serum transferrin). Reference ranges
are: serum iron, 40–150 mg/dL; serum ferritin in men, 18–
440 ng/mL; serum ferritin in premenopausal women, 8–120 ng/
mL; serum ferritin in postmenopausal women, 30–300 ng/mL;
HIC, 300–1400 mg iron/g of dry liver tissue weight; transferrin
saturation, 16–45%. The cut-off criteria for significant alcohol
consumption were: ,20 g/day (females) and ,60 g/day (males)
[19,20]. The presence of major liver disorders (e.g., viral hepatitis,
heavy alcohol consumption, Wilson disease, primary biliary
cirrhosis) was excluded by the appropriate clinical workup [20].
Informed consent was obtained from all subjects and the study was
approved by the Ethics Committees of the participating centers.
The liver-healthy control subjects were recruited in the medical
centers of Bern (Switzerland) and Erlangen (Germany).
Mutation Detection
Genomic DNA was isolated from peripheral whole blood using
an established DNA isolation kit (Qiagen GmbH, Hilden,
Germany). For hemochromatosis patients, all 15 K8 and K18
exons and their adjacent exon-intron boundaries were amplified
using previously described primers and a mixture of T Taq and
Optimase Polymerases (Transgenomic, Omaha, NE) [24], while
only K8 exons 1 and 6 were analyzed in control subjects. All
amplicons were pre-screened with denaturing high pressure liquid
chromatography (DHPLC) [24]. Probes with abnormal elution
peak were purified with a QIAquick PCR purification kit (Qiagen)
and sequenced in both directions using an ABI PRISM 377 DNA
Sequencer (Applied Biosystems, Foster City, CA). The location of
the coding KRT8/KRT18 variants was assigned based on the
mRNA sequences NM 002273.2 and NM 000224.2, respectively,
while genomic sequences M34482.1 and AF179904.1 were
employed for assignment of non-coding variants (www.ncbi.nlm.
nih.gov). New genetic variants were reported in GenBank
(accession numbers for K8 Q169E, R275W and E339A are
rs199422323, rs199422324 and rs144044115, respectively).
Mouse Experiments
To study whether the presence of keratin variants affects hepatic
iron accumulation, previously described transgenic mice (3–4
months old, four male/group) overexpressing human wild-type K8
(K8 WT) or the K8 G62C variant [8] were fed ad libitum with 3%
carbonyl iron (Sigma-Aldrich, Germany)-containing diet (5001
Labdiet, Brentwood, MO) for one month. Age-matched male mice
kept on a standard diet were used as controls. Mice were
euthanized by CO2 inhalation and blood was collected by
intracardiac aspiration to measure serum alanine aminotransferase
(ALT) levels. Livers were removed and cut into pieces for: (i)
fixation in 10% formaldehyde for histological staining, (ii) snap
freezing to measure hepatic iron concentration (HIC), or
submerging into RNAlater stabilization reagent (Qiagen) for
RNA analysis. Histological images were taken by Olympus
BX40 with spot insight QE camera. The mRNA was transcribed
into cDNA using oligo-dT primers and Superscript II reverse
transcriptase (Invitrogen, Germany). Quantitative real-time poly-
merase chain reaction (RT-PCR) was carried out with SYBR
green Master Mix (Applied Biosystems; Foster City, CA) and
performed in duplicate using specific mouse hepcidin (encoded by
Hamp gene), collagen1 (Col1a1), smooth muscle a-actin (SMA) and
Hemochromatosis and Keratins
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protein as an internal control (Table S2). All animals received
humane care and their use was approved by the Institutional
Animal Care Committee.
Determination of Hepatocellular Iron Toxicity
To test whether the presence of keratin variants influences
hepatocellular iron toxicity, we isolated primary hepatocytes from
K8 WT and G62C males as described before [8]. Briefly, the
portal vein was cannulated and perfused with preheated liver
Perfusion medium (Gibco 17701, Invitrogen, Darmstadt, Ger-
many) then with pre-warmed 67 m/mg Worthington type I
collagenase-containing DMEM medium (CellSystems Biotechno-
logie Vertrieb GmbH, Troisdorf, Germany). The cell suspension
was collected from extirpated livers, filtered through 100 mm-cell
strainers (BD Falcon 9322799, Heidelberg, Germany) and
centrifuged at 50 g for 1 min. The pellet was washed three times,
and the isolated cells were cultured in hepatocyte culture medium
(Gibco Hepatozym-SFM 17705, Darmstadt, Germany) supple-
mented with 10% FCS, 1% penicillin-streptomycin and L-
Glutamine. To mimic the acute iron toxicity, hepatocytes were
subjected to 100 mM iron-nitrilotriacetic acid complex (FeNTA)
for 48 hours with the molar ratio of NTA/Fe
3+ of 2:1 [25,26].
Untreated cells or cells treated with 100 mM nitrilotriacetic acid
(NTA) without Fe were used as controls. Cell viability was
determined using a commercially available MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
(Roche Cell Proliferation Kit I). Lactate dehydrogenase (LDH)
and ALT were measured from cell supernatants.
Statistical Analysis
The unpaired two-tailed t or chi-square tests were used, and P
values less than 0.05 were considered statistically significant.
Results
Patient Demographics
The clinical characteristics of the previously described cohort of
162 subjects carrying homozygous HFE C282Y mutation are
displayed in Table 1; [19,20]. Most patients were males and
harbored a significantly higher risk to develop liver cirrhosis than
females (p,0.0001). Similarly, all assessed parameters of iron
metabolism were markedly higher in males compared to females
(Table 1) (ferritin p,0.0001, HIC p=0.001, HII p=0.003). Only a
minority of patients had significant alcohol consumption.
Analysis for Presence of Coding K8/K18 Variants
Genetic analysis of the entire coding regions of K8/K18
identified 10 heterozygous K8 variants that result in amino acid
substitution (overall variant frequency 6.2%, Table 2). K8 G62C
and K8 R341H were the most frequent amino-acid-altering
variants and were found in three and four independent patients,
respectively. One patient harbored two heterozygous amino-acid
altering K8 variants (K8 A319S+R341H). Two novel variants
were detected that had not been described before. One of the
novel variants, KRT8 505 CRG resulting in a K8 Q169E
substitution within the rod domain (subdomain 1B), was found in
two patients. The other novel variant, KRT8 823 CRT that codes
for a K8 R275W substitution in the L2 linker sequence of KRT8,
was found in one patient. The novel variants were detected in non-
cirrhotic patients, and the involved amino acid residues are
remarkably conserved among species and among some type II
keratins (Figure S1). In addition to amino-acid-altering variants, a
previously described common K8 L227L polymorphism was
observed (not shown) [27].
An analysis of K8 variant hotspots in 234 liver healthy Central
European subjects revealed a comparable variant frequency of
8.1% with K8 R341H and G62C variants being found in nine and
six subjects respectively. One novel variant (E339A) was detected
that had not been described before. The frequency of amino-acid-
altering variants was similar in cirrhotic and non-cirrhotic patients
(6.6% vs. 6.1%). Among the described keratin variants, only K8
G62C and R341H were previously clearly implicated in liver
disease development [4] and the frequency of these two variants
was somewhat higher in cirrhotic versus non-cirrhotic patients
(6.6% vs 3.0%; ‘‘significant variants’’ in Table 2). This was mainly
due to the K8 G62C variant, which was found exclusively in
patients with liver cirrhosis (Table 2) but the numbers were too
small to reach statistical significance.
Characterization of the Non-Coding K8/K18 Variants
Our genetic analysis identified 9 non-coding heterozygous K8
variants (Table 3). Among these, an intronic KRT8 IVS7+10delC
deletion was the most common variant and exclusively associated
with K8 R341H substitution as described before [28]. IV-
S6+46A.T intronic variant was the only intronic variant found
in the control group and was seen in one subject (out of 234). The
presence of additional intronic variants (IVS7+20G.A and
IVS8+31C.T) was not analyzed in the control group. When
compound exonic-intronic variants were excluded, ‘‘pure’’ intro-
nic variants (labeled as ‘‘total intronic variants in Table 3) were
Table 1. Patient Demographics and Biochemical Values.
Demographics Male Female Total # Patients without data (%)
# of patients (%) 120 (74.5) 41 (25.5) 162 (100) 1(0.6)
Age at LBx, mean 6 SD (years) 50613 52612 50613 -
Cirrhosis yes/no (%) 58/60 (49/51) 3/38 (7/93) 61/99(38/62) -
Alcohol consumption (yes/no) 6/104 4/31 10/135 19 (11.7)
Serum iron (mg/dL), mean6 SD 213643 195635 208641 38 (23.5)
Transferrin Saturation (%), mean6 SD 87617 74619 84618 29 (17.9)
Serum ferritin (ng/mL), mean6 SD** 250161953 7116592 208161891 17 (10.5)
HIC (mg/g dry weight), mean6 SD 1333968537 741666945 1167168518 59 (36.4)
HII, mean6 SD 5.263.6 2.963.2 4.663.7 55 (34.0)
Abbreviations: LBx:liver biopsy; SD: standard deviation; HIC: hepatic iron concentration; HII:hepatic iron index.
doi:10.1371/journal.pone.0032669.t001
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patients carrying ‘‘pure’’ intronic variants displayed liver cirrhosis
(8.2%), while only one subject did not have cirrhosis. Conse-
quently, the non-coding KRT8 variants were significantly over-
represented in cirrhotic patients (p=0.02). However, neither
intronic nor exonic keratin variants associated with iron
accumulation in hemochromatosis patients as suggested by similar
levels for serum iron, transferrin, transferrin saturation, ferritin
and HIC and HII indices (Table 4). On the other hand, cirrhotic
subjects were older and had higher transferrin saturation than
non-cirrhotic patients (Table S1).
The K8 G62C Variant Does Not Alter Experimental Iron
Accumulation
Given that all patients harboring the K8 G62C variant displayed
liver fibrosis, we used previously-characterized transgenic mice that
overexpress K8 G62C and control mice that overexpress WT K8
[8] to test whether K8 G62C affects iron accumulation. As
expected, both untreated and iron-fed K8 WT and K8 G62C mice
had normal ALT levels (Figure 1A), and did not display any
histological signs of liver damage (not shown). Iron-feeding led to a
dramatic increase in hepatic iron, which were slightly more
pronounced in K8 WT animals; however, the difference between
genotypes is not statistically significant (p=0.08; Figure 1B).
Furthermore, both genotypes expressed nearly identical levels of
the iron uptake-regulating hormone hepcidin (Hamp) and compa-
rable levels of fibrosis-associated genes collagen 1 (Col1a1), smooth
muscle a-actin (SMA) and transforming growth factor-b (TGF-b)
(Figure S2). In addition, Perl’s Prussian blue staining revealed a
similar pattern of iron accumulation in both genotypes (Figure 1C).
The K8 G62C Variant Does Not Increase Mouse
Hepatocyte Iron Toxicity Ex-Vivo
To test whether the presence of K8 G62C variant affects
hepatocellular iron toxicity, primary hepatocytes from K8 WT
and G62C mice were treated with FeNTA. FeNTA exposure led
to significant increase in the release of ALT and LDH into the cell
culture supernatant; which, however, did not differ significantly
between the genotypes (Figure 2A, B). Similarly, addition of
FeNTA reduced cell viability in both K8 WT and G62C
hepatocytes to a similar extent (Figure 2C), thereby suggesting
that the presence of K8 G62C does not enhance hepatocyte iron
toxicity.
Discussion
In the study herein, we first analyzed HHC samples for the
presence of K8/K18 variants. Amino-acid-altering keratin vari-
Table 2. Distribution of Exonic Keratin Variants.
KRT8 Cirrhosis (# and % of patient) Total # of variant (%) Total # of control (%)
Variant Nucleotide Location Yes (61/38) No (99/62) 162 234
G62C GGCRTGC Exon 1 3 0 3 (1.85) 6 (2.6)
I63V* ATCRGTC Exon 1 0 0 0 2 (0.8)
Q169E
{ CAGRGAG Exon 2 0 2 2 (1.23) N.T.
R275W
{ CGGRTGG Exon 5 0 1 1 (0.62) N.T.
A319S* GCTRTCT Exon 5 0 1
$ 1 (0.62) N.T.
E339A
{,* GAGRGCG Exon 6 0 0 0 1 (0.4)
R341H CGTRCAT Exon 6 1 3
$ 4 (2.50) 9 (3.8)
# Patients with any variant (%) 4 (6.56) 6
& (6.06) 10 (6.17) 19 (8.1)
# Patients with significant variant (%) 4 (6.56) 3 (3.03) 7 (4.32) 15 (6.4)
The table displays the number of patients with and without liver cirrhosis for the listed keratin variants.
*The highlighted variant is considered to be a ‘‘polymorphism’’ rather than a ‘‘mutation’’ that is likely to have biologic significance.
{Novel variants which were not previously described.
$One female patient harbored 2 independent amino acid altering KRT8 variants (R341H+A319S). N.T.not tested.
doi:10.1371/journal.pone.0032669.t002
Table 3. Distribution of Non-Coding Keratin Variants.
KRT8 Cirrhosis (# and % of patient) Total # of variant (%)
Variant Location Yes (61/38) No (99/62) 162
IVS7+10delC* Intronic 1 3 4
IVS6+46A.T
{ Intronic 1 1 2 (1.23)
IVS7+20G.A Intronic 3 0 3 (1.85)
IVS8+31C.T3 9-UTR 1 0 1 (0.62)
Total intronic variant (%) 5 (8.20)** 1 (1.01)** 6 (3.70)
The table displays the number of patients with and without liver cirrhosis for the listed keratin variants.
*IVS7+10delC variant completely associates with KRT8 R341H variant and is not included in the count of total intronic variants.
{The highlighted variant was found only in one control subject (out of 234).
**p=0.02.
doi:10.1371/journal.pone.0032669.t003
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6.2%) and a similar frequency of keratin variants was seen in the
control group (8.1%). In contrast, substantially higher keratin
variant frequencies (.10%) were previously described in patients
with end-stage liver disease or acute liver failure, which is likely
due to the enrichment of keratin variants in patients with severe
liver disease [5,7]. On the other hand, comparable keratin variant
frequencies were seen in two European studies, which analyzed
patients with chronic hepatitis C infection and primary biliary
cirrhosis that included patients with all ranges of liver disease
severity [6,28].
Among single point mutations, we identified four patients with
K8 R341H variant (variant frequency 2.5%), which is comparable
with the frequency seen in liver-healthy Caucasians [7] and
hitherto analyzed control subjects (variant frequency 3.8%), but
lower than a previously analyzed US HHC patient cohort (variant
frequency 7.6%, p=0.08, [16]). Furthermore, we observed a novel
K8 Q169E variant in two unrelated HHC patients, which we had
Table 4. The Clinical Features of Hemochromatosis Patients Harboring Exonic and Intronic Keratin 8 Variants.
Presence of Exonic Variants Presence of Intronic Variants
Demographics YES (n=10) NO (n=152) YES (n=6) NO (n=156)
Sex (M/F) 7/3 113/38 5/1 115/40
Age at LBx, mean 6 SD (years) 55611 50613 59685 0 613
Cirrhosis (yes/no) 4/6 57/93 5/1 56/98
Alcohol consumption (yes/no) 0/6 10/127 0/6 10/127
Serum iron (mg/dl), mean6 SD 216631 208642- 202629 209642
Transferrin Saturation (%), mean6 SD 84620 84618 95668 4 618
Serum ferritin (mg/l), mean6 SD 237762147 240964703 216661786 207761901
HIC (mg/g), mean6 SD 1401268560 1155268543 1276569145 1162768539
HII, mean6 SD 5.463.6 4.563.7 3.762.3 4.663.7
Abbreviations: LBx:liver biopsy; SD: standard deviation; HIC: hepatic iron concentration; HII: hepatic iron index.
Note that intronic keratin variants were preferentially found in male subjects (p=0.09 for distribution among the sexes).
doi:10.1371/journal.pone.0032669.t004
Figure 1. The K8 G62C variant does not influence the extent of hepatocellular iron accumulation. To test, whether hepatocellular iron
accumulation is affected by the presence of keratin variants, transgenic mice overexpressing wild-type human keratin 8 (K8 WT) or K8 G62C variant
were fed with 3% carbonyl iron-containing diet for one month (Iron) and compared to age-matched animals kept on standard diet (Control) (n=4
mice/group). Iron-feeding did not lead to an increase in serum ALT (A), but caused a significant elevation in hepatic iron concentration (HIC) (B).
There was no significant difference in ALT or HIC levels between K8 WT and G62C mice after iron feeding. (C) Perl’s Prussian blue staining revealed a
similar pattern of iron deposition in both mouse lines. Scale bar=200 mm.
doi:10.1371/journal.pone.0032669.g001
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diseases [5,7]. The K8 Q169E variant introduces a charged amino
acid, and leads to replacement of the highly conserved K8 Q169.
Given that no mutations have been reported in homologous
keratin residues among other type II keratins (http://www.interfil.
org/), further studies are needed to address the potential
pathogenic role of this variant.
While the amino-acid altering K8/K18 variants exhibited
similar frequencies in HHC patients with and without liver
cirrhosis, all patients harboring the K8 G62C variant had liver
cirrhosis. This mutation might therefore be of particular relevance
in HHC. This hypothesis is further supported by the fact that this
variant introduces a cysteine into the K8 backbone, which
normally lacks cysteines, and leads to keratin crosslinking and
impairment of keratin filament reorganization upon oxidative
stress [29]. Given the established role of oxidative stress in HHC
development as well as the finding that an introduction of cysteine
into otherwise cysteine-less K18 predisposes mice to oxidative
injury [17,18], we used previously described transgenic mice
overexpressing K8 G62C to study the importance of K8 G62C in
iron-overload [24]. However, K8 G62C presence did not
accelerate iron accumulation or augment iron-induced hepatocel-
lular damage and apoptosis (Figure 1, 2). We posit that if K8
G62C does indeed predispose to liver disease progression, then it
does so in a manner that is independent of iron accumulation.
In summary, the combination of genetic and experimental data
suggests that in contrast to hepatitis C, primary biliary cirrhosis
and acute liver failure [5,7], amino-acid altering variants may not
contribute to liver disease development in HHC. This finding is
not surprising since different liver disorders were shown to posses
their unique genetic disease-modifiers [30]. For example, factors
modifying iron accumulation might be particularly important in
hereditary hemochromatosis, while genes affecting inflammatory
response and lipid metabolism may contribute to disease
progression in patients with hepatitis C infection and alcoholic/
non-alcoholic liver disease, respectively [13–15] [30].
Unlike the exonic variants, the intronic variants were shown to
be overrepresented in HHC patients with liver cirrhosis. This
finding represents the first such liver disease association since
intronic K8/K18 variants did not associate with liver fibrosis
development in patients with chronic hepatitis C infection [28].
However, intronic variants may very well be functional, given that
introns harbour multiple functional elements that regulate
alternative splicing or transcription [31]. Furthermore, there was
a trend for intronic variants to be more abundant in primary
biliary cirrhosis patients as compared with the control group;
however their association with liver disease progression was not
analyzed [6]. Given the limited number of patients analyzed in the
present study and the fact that there are no available data about
the biological significance of the observed intronic variants, further
studies are needed to determine their role in liver disease.
Supporting Information
Figure S1 Conservation of novel K8 variants among
species and type II keratins. The sequences surrounding the
amino acids K8 Q169 (A, B) and K8 R275W (C, D) are displayed
for selected species (A, C) and type II keratins (B, D). The
sequences illustrate the single nucleotide variations leading to the
highlighted amino acid change (E, F). Note that K8 Q169 is highly
conserved among species and among type II keratins, while K8
R275 amino acid is highly conserved among species, and is also
conserved from a charge perspective among type II keratins. The
figures were assembled using the following reference sequences:
K8: NM 002273.3 (Homo sapiens), NM 19937.1 (Rattus
norvegicus), NM 031170.2 (Mus musculus), BC 044116.1
(Xenopus laevis) and NM 200080.2 (Danio rerio); Type II
Keratins: NM 006121.3 (KRT1), NM 000423.2 (KRT2a), NM
015848.4 (KRT2p), NM 057088.2 (KRT3), NM 002272.3 (KRT4),
NM 000424.3 (KRT5), NM 005554.3 (KRT6A), NM 005555.3
(KRT6B), NM 005556.3 (KRT7).
(TIF)
Figure S2 mRNA expression of fibrosis-related genes
and hepcidin does not differ among K8 WT and G62C
fed iron-rich diet. WT mRNA levels are set at 1.0 and G62C
Figure 2. The K8 G62C variant does not affect iron toxicity in ex
vivo cultured hepatocytes. To study the hepatocellular iron toxicity,
primary hepatocytes from transgenic animals overexpressing K8 WT or
K8 G62C were cultured in normal media (Control) or media
supplemented with 100 mM nitrilotriacetic acid (NTA) or 100 mM iron-
NTA (FeNTA) for 24 hours. FeNTA, but not NTA treatment led to a
significant increase in LDH (A) and ALT levels (C) in cell culture
supernatants together with significant decrease in cell viability as
assessed by MTT assay (B). The enzyme levels and cell viability did not
differ significantly between K8 WT and K8 G62C hepatocytes.
doi:10.1371/journal.pone.0032669.g002
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32669mRNA levels of the indicated transcripts are displayed relative to
WT. mRNA was isolated from 4 independent livers per genotype.
(TIF)
Table S1 The clinical characteristics of the previously described
cohort of 162 subjects carrying homozygous HFE C282Y
mutation (cirrhotic patients vs non-cirrhotic patients).
(DOC)
Table S2 Sequence of primers used for quantitative real time-
PCR and length of the amplified products.
(DOC)
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